About: Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients
Creator	Otu, Akaninyene Ameh, Soter Asuquo, Marcus Effa, Emmanuel Egbe, William Ekpenyong, Andrew Etok, Margaret Gbotosho, Oluwabukola Guck, Jochen Ikpeme, Anthonia Ita, Okokon Udoh, Ubong Umoh, Victor
Source	MedRxiv
abstract	The coronavirus disease 2019 (COVID-19) is now a pandemic with devastating social and economic consequences. The extent of the spread of COVID-19 within populations is uncertain since diagnostic tests have not been carried out on all eligible persons and doing such diagnostic tests on everyone is much less feasible in developing countries such as Nigeria. Tests for antibodies to SARS-CoV-2, the virus that causes COVID-19, are more affordable, readily available, and require minimal training than current diagnostic tests. Employing a seroepidemiological strategy, serological tests were conducted on 66 volunteering staff and patients at the University of Calabar Teaching Hospital (UCTH), a Federal Government owned tertiary healthcare facility, to determine the extent of exposure to SARS-CoV-2, from 17th to 25th June 2020. Using a COVID-19 IgG/IgM Rapid Test Cassette with emergency use authorization (EUA) from the Food and Drug Administration (FDA) of the United States, it was observed that of the 66 samples tested, 5 (7.6%) were both IgG and IgM positive and 17 (26%) were IgG positive. Moreover, for 44 of the 66 participants, simultaneous tests were carried out using a rapid test kit from a different manufacturer but without FDA-EUA and all the results completely matched with the FDA-EUA kit, except one case where the FDA-EUA kit showed positive for both IgG and IgM while the other kit was positive only for IgM. The 26% positive IgG indicates a high exposure rate for the hospital staff and patients and points to community transmission where the facility is situated. Hence, immediate activation of WHO guidelines for controlling community transmission is called for. These results can further serve as a pilot study to guide public health policies in response to COVID-19 pandemic in both the general population and in healthcare settings.
has issue date	2020-07-04(xsd:dateTime)
bibo:doi	10.1101/2020.07.02.20145441
has license	medrxiv
sha1sum (hex)	4ba4f4bc83ae16fb8cbe02e40fd6973a94f0a0aa
schema:url	https://doi.org/10.1101/2020.07.02.20145441
resource representing a document's title	Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients
resource representing a document's body	covid:4ba4f4bc83ae16fb8cbe02e40fd6973a94f0a0aa#body_text
is schema:about of	named entity 'manufacturer' named entity 'healthcare' named entity 'antibodies' named entity 'authorization' named entity 'IgG' named entity 'EMERGENCY USE AUTHORIZATION' named entity 'EXCEPT' named entity 'PARTICIPANTS' named entity 'EXTENT OF' named entity 'TO GUIDE' named entity 'UNITED STATES' named entity 'GENERAL POPULATION' covid:arg/4ba4f4bc83ae16fb8cbe02e40fd6973a94f0a0aa named entity 'June' named entity 'Calabar' named entity 'training' named entity 'simultaneous' named entity 'IgM' named entity 'Tests' named entity 'points' named entity 'blood collection' named entity 'rapid' named entity 'IgG' named entity 'EUA' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'consequences' named entity 'IgM' named entity 'June 2020' named entity 'FDA' named entity 'COVID-19' named entity 'EUA' named entity 'community transmission' named entity 'IgG' named entity 'tertiary healthcare' named entity 'WHO' named entity 'FDA' named entity 'EUA' named entity 'diagnostic tests' named entity 'diagnostic tests' named entity 'Rapid Test' named entity 'EUA' named entity 'virus' named entity 'community transmission' named entity 'Prevalence' named entity 'diagnostic tests' named entity 'pandemic' named entity 'IgG' named entity 'advanced countries' named entity 'antibody tests' named entity 'reverse transcriptase polymerase chain reaction' named entity 'Center for Disease Control' named entity 'RT-PCR' named entity 'PCR' named entity 'diagnostic testing' named entity 'FDA' named entity 'IgA' named entity 'EUA' named entity 'IgG' named entity 'medRxiv' named entity 'COVID' named entity 'IgG' named entity 'COVID' named entity 'infection' named entity 'IgM' named entity 'RT-PCR' named entity 'EUA' named entity 'IgG' named entity 'EUA' named entity 'preprint' named entity 'hand washing' named entity 'ethical approval' named entity 'IgM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software